Medicare Expands Coverage for NeoGenomics RaDaR ST Assay for Immunotherapy
NeoGenomics' RaDaR ST assay received expanded Medicare coverage for immunotherapy monitoring in late-stage solid tumors, adding to its existing indications. The assay helps track treatment response and distinguish true progress from inflammation. According to the company, it detects circulating tumor DNA at low levels, supporting recurrence risk assessment and treatment monitoring.
How this was made
The 30-second read
Why it matters
The coverage adds a third reimbursable indication, potentially increasing test volumes and supporting revenue growth for NeoGenomics.
Market read
Regulatory coverage expansion is a material catalyst for NeoGenomics, likely influencing its stock price.
What to watch
Pending CMS submissions could delay full market impact; competition from other MRD platforms.
Background
NeoGenomics announced the CMS decision expanding Medicare coverage for its RaDaR ST assay, now covering immunotherapy monitoring in late-stage solid tumors.
Market effects
May encourage broader payer acceptance of molecular MRD assays across oncology.
U.S. diagnostic and oncology markets see increased reimbursement support.
Sets precedent for other regions to consider similar coverage policies.
Counterpoint
Reimbursement may be limited by utilization criteria, tempering revenue upside.
Key entities
- CompanyNeoGenomics
Provider of molecular diagnostic assays, ticker NGEN.
- RegulatorCMS
Centers for Medicare & Medicaid Services, granting coverage.
